Search research articles
Contact Us
Filters
Showing results (31-40 of 124) with videos related to
Page
of 13
Sort By:
Urologie (Heidelberg, Germany)
|
September 1, 2023
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]
Niklas Klümper, Markus Eckstein, Frank Kunath, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
September 27, 2024
Prostaglandin E<sub>2</sub> signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production
Martina Feger, Katharina Hammerschmidt, Ilona Liesche, et al.
Journal of Cancer Research and Clinical Oncology
|
October 29, 2018
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
Steffen Rausch, Daniel Schollenberger, Joerg Hennenlotter, et al.
Expert Review of Anticancer Therapy
|
February 7, 2017
Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Inês Anselmo Da Costa, Steffen Rausch, Stephan Kruck, et al.
Central European Journal of Urology
|
June 30, 2026
Topographical and stage-related expression of nectin-4 in prostate cancer
Radion Garaz, Jörg Hennenlotter, Veronika Bahlinger, et al.
Asian Journal of Andrology
|
December 30, 2017
Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
Miriam Hegemann, Moritz Maas, Steffen Rausch, et al.
Translational Andrology and Urology
|
November 22, 2021
Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
Stefan Aufderklamm, Jörg Hennenlotter, Steffen Rausch, et al.
World Journal of Urology
|
February 26, 2022
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
Viktoria Stühler, Lisa Herrmann, Moritz Maas, et al.
World Journal of Urology
|
January 20, 2024
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma
Viktoria Stühler, Bilal Alemi, Steffen Rausch, et al.
Urolithiasis
|
November 23, 2024
Potential impacts to human health from climate change: A comparative life-cycle assessment of single-use versus reusable devices flexible ureteroscopes
Marlene Thöne, Jan Lask, Jörg Hennenlotter, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 124) with videos related to
Sort By:
Page
of 13
Urologie (Heidelberg, Germany)
|
September 1, 2023
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]
Niklas Klümper, Markus Eckstein, Frank Kunath, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
September 27, 2024
Prostaglandin E<sub>2</sub> signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production
Martina Feger, Katharina Hammerschmidt, Ilona Liesche, et al.
Journal of Cancer Research and Clinical Oncology
|
October 29, 2018
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
Steffen Rausch, Daniel Schollenberger, Joerg Hennenlotter, et al.
Expert Review of Anticancer Therapy
|
February 7, 2017
Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Inês Anselmo Da Costa, Steffen Rausch, Stephan Kruck, et al.
Central European Journal of Urology
|
June 30, 2026
Topographical and stage-related expression of nectin-4 in prostate cancer
Radion Garaz, Jörg Hennenlotter, Veronika Bahlinger, et al.
Asian Journal of Andrology
|
December 30, 2017
Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
Miriam Hegemann, Moritz Maas, Steffen Rausch, et al.
Translational Andrology and Urology
|
November 22, 2021
Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
Stefan Aufderklamm, Jörg Hennenlotter, Steffen Rausch, et al.
World Journal of Urology
|
February 26, 2022
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
Viktoria Stühler, Lisa Herrmann, Moritz Maas, et al.
World Journal of Urology
|
January 20, 2024
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma
Viktoria Stühler, Bilal Alemi, Steffen Rausch, et al.
Urolithiasis
|
November 23, 2024
Potential impacts to human health from climate change: A comparative life-cycle assessment of single-use versus reusable devices flexible ureteroscopes
Marlene Thöne, Jan Lask, Jörg Hennenlotter, et al.
Page
of 13